NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas.

@article{Cho2014NEO212TC,
  title={NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas.},
  author={Hee-Yeon Cho and Weijun Wang and Niyati Jhaveri and David Jungpa Lee and Natasha Sharma and Louis Dubeau and Axel H Sch{\"o}nthal and Florence M. Hofman and Thomas C. Chen},
  journal={Molecular cancer therapeutics},
  year={2014},
  volume={13 8},
  pages={2004-17}
}
Patients with glioblastoma multiforme (GBM), a malignant primary brain tumor, inevitably develop resistance to standard-of-care chemotherapy, temozolomide. This study explores the effects of the novel agent NEO212, a conjugate of temozolomide to perillyl alcohol, on temozolomide-resistant gliomas. NEO212 was tested for cytotoxic activity on three human temozolomide-resistant glioma cell lines, which were resistant to temozolomide based on overexpression of the base excision repair (BER) pathway… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 52 references

Bjerkvig R.Molecular mechanisms of temozolomide resistance in glioblastoma multiforme

TC Johannessen
Expert Rev Anticancer Ther 2012;12:635–42 • 2012
View 4 Excerpts
Highly Influenced

A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients

RossoL, BrockCS, +3 authors FE Turkheimer
Cancer Res • 2009
View 4 Excerpts
Highly Influenced

Targeting the checkpoint kinases: chemosensitization versus chemoprotection

Nature Reviews Cancer • 2004
View 3 Excerpts
Highly Influenced

Efficacy and safety of bevacizumab in glioblastomas

S De Fazio, E Russo, M Ammendola, E Donato Di Paola, G. De Sarro
Curr Med Chem • 2012
View 1 Excerpt

Similar Papers

Loading similar papers…